logo
logo
IQV stock ticker logo

IQVIA Holdings Inc.

NYSE•IQV
CEO: Mr. Ari Bousbib
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2013-05-09
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Contact Information
2400 Ellis Road, Durham, NC, 27703, United States
919-998-2000
www.iqvia.com
Market Cap
$27.95B
P/E (TTM)
20.6
30.2
Dividend Yield
--
52W High
$247.05
52W Low
$134.65
52W Range
27%
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$4.36B+0.00%
4-Quarter Trend

EPS

$3.02+0.00%
4-Quarter Trend

FCF

$561.00M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth 5.9% 2025 Revenues reached $16.31B, growing 5.9% over 2024, driven by constant currency growth of 4.8% across segments.
R&D Backlog Expansion Contracted backlog for Research & Development Solutions grew to $32.7B by year-end 2025, expecting $8.3B conversion next twelve months.
Acquisition Investment Surge Investing cash used $2.31B in 2025, driven by $1.71B net cash deployed for strategic business acquisitions across all segments.
Diluted EPS Improvement Diluted EPS was $7.84 in 2025, marking an increase of $0.35 compared to the $7.49 reported in the prior year.

Risk Factors

Contract Loss Potential Potential loss or delay of large contracts could adversely affect results due to 30 to 90 day termination notice provisions in R&D Solutions.
Data Supplier Dependency Reliance on numerous third-party data suppliers; restrictions or failures to adhere to quality standards could materially impact operating results.
Increased Restructuring Costs Incurred $105M in restructuring costs during 2025 due to ongoing global operations streamlining efforts expected to continue into 2026.
Evolving Privacy Regulations Evolving global data protection and privacy laws create compliance uncertainty, requiring additional security measures and potential expenditures.

Outlook

Segment Reporting Update Updating segment reporting effective January 1, 2026, renaming TAS to Commercial Solutions and realigning Real-World offerings.
AI and Technology Focus Strategy centers on innovating through IQVIA Connected Intelligence leveraging Healthcare-grade AI capabilities for efficiency and insights.
Broader Marketplace Penetration Plan to expand offerings penetration to broader healthcare marketplace, serving payers, providers, governments, and NGOs.
Strategic Acquisition Growth Expect continued strategic acquisitions to strengthen value proposition across life sciences, payer, and provider sectors moving forward.

Peer Comparison

Revenue (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
HUM stock ticker logoHUM
$129.66B
+10.1%
HLN stock ticker logoHLN
$25.31B
+13.7%

Gross Margin (Latest Quarter)

ONC stock ticker logoONC
90.5%
+3.1pp
INSM stock ticker logoINSM
82.5%
-18.6pp
ILMN stock ticker logoILMN
67.0%
-1.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CAH$51.08B30.8-58.9%15.5%
HLN$44.67B22.39.4%26.4%
ALC$37.69B38.64.4%16.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.5%
Moderate Growth
4Q Net Income CAGR
27.3%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data